| 216048 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Antitumor effector B cells directly kill tumor cells involving the CXCL12/CXCR4 pathway and their therapeutic efficacy is enhanced by IL-2 |
2015-11-04 |
10.1186/2051-1426-3-s2-p27 |
Li Qiao, Xia Yang |
| 216047 |
BMC CANCER |
From prospective biobanking to precision medicine: BIO-RAIDs – an EU study protocol in cervical cancer |
2015-11-04 |
10.1186/s12885-015-1801-0 |
Ngo Charlotte, RAIDs consortium http://www.raids-fp7.eu/, Samuels Sanne, Bagrintseva Ksenia, Slocker Andrea, Hupé Philippe, Kenter Gemma, Popovic Marina, Samet Nina, Tresca Patricia, von der Leyen Heiko, Deutsch Eric, Rouzier Roman, Belin Lisa, Kamal Maud, Scholl Suzy |
| 216046 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Enhancing anti-tumor immunity through local gene delivery to lymph nodes |
2015-11-04 |
10.1186/2051-1426-3-s2-p431 |
Dold Neil M, Jewell Christopher M |
| 216045 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis |
2015-11-04 |
10.1186/2051-1426-3-s2-o15 |
Dhodapkar Kavita, Bar Noffar, Boddupalli Chandra Sekhar, Kadaveru Krishna, Mai Zifeng, Deng Yanhong, Sznol Mario, Dhodapkar Madhav |
| 216044 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM) |
2015-11-04 |
10.1186/2051-1426-3-s2-p161 |
Hassan Raffit, Alley Evan, Kindler Hedy, Antonia Scott, Jahan Thierry, Thomas Anish, Honarmand Somayeh, Murphy Aimee L, Grous John J, Brockstedt Dirk G |
| 216043 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors |
2015-11-04 |
10.1186/2051-1426-3-s2-p180 |
Hecht J Randolph, Raman Steven, Sze Daniel Y, Lockhart A Craig, Moss Rebecca A, Liu Kate, Chou Jeffrey, Reid Tony |
| 216042 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC |
2015-11-04 |
10.1186/2051-1426-3-s2-p171 |
Rizvi Naiyer, Barlesi Fabrice, Brahmer Julie, Felip Enriqueta, Forde Patrick, Garassino Marina, Goldberg Sarah, Vansteenkiste Johan, Jarkowski Anthony, McIntosh Stuart, Zhao Luping, Antonia Scott |
| 216041 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
A monocyte and interferon based cell therapy for the treatment of ovarian cancer |
2015-11-04 |
10.1186/2051-1426-3-s2-p222 |
Green Daniel, Johnson Chase, Zoon Kathryn |
| 216040 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Colony stimulating factors secreted by irradiated autologous tumor cell vaccines inhibit immunity |
2015-11-04 |
10.1186/2051-1426-3-s2-p448 |
Ravindranathan Sruthi, Smith Sean G, Nguyen Khue, Zaharoff David A |
| 216039 |
BMC MUSCULOSKELETAL DISORDERS |
Association between neck and shoulder pain, back pain, low back pain and body composition parameters among the Japanese general population |
2015-11-04 |
10.1186/s12891-015-0759-z |
Iizuka Yoichi, Iizuka Haku, Mieda Tokue, Tajika Tsuyoshi, Yamamoto Atsushi, Ohsawa Takashi, Sasaki Tsuyoshi, Takagishi Kenji |
